Brain plaques in multiple sclerosis patients
In MAGNETOM 7T At the NeuroCure Clinical Research Center at Charité Medical University in Berlin, researchers used MAGNETOM 7 Tesla1 magnetic resonance imaging (MRI) system with an A T1-weighted magnetization-prepared rapid acquisition and multiple gradient-echo (MP-RAGE) protocol helps to clearly visualize cortical lesions in multiple sclerosis (MS) patients.
From black holes…
T1-weighted sequences are used to differentiate irreversible brain tissue damage commonly called “black holes”. Black holes are associated with the progression of MS and cerebral atrophy. Spin-echo T1-weighted images show a proportion of T2 hyperintense lesions or black holes that appear hypointense to the surrounding normal-appearing white matter for an extended period of time. The study included 20 patients with relapsing-remitting MS from the outpatient clinics of the NeuroCure Clinical Research Center. There were 11 male and nine female patients with a mean age of 42 years and mean disease duration of 3.1 years. For comparison purposes, 14 healthy control subjects also were enrolled. All 34 subjects received brain scans using the 7 Tesla MAGNETOM MRI system from Siemens with a 24-channel head coil. In addition, a subgroup of 18 patients with MS received brain scans with a 1.5 Tesla system.
…to clarity in imaging
The analysis found that the use of MPRAGE in 7T provided evidence for a total of 728 lesions, compared with 584 lesions with 7 Tesla FLASH and 399 lesions with conventional 1.5 Tesla MPRAGE. In addition, 7 Tesla T2-weighted FLASH revealed 604 cerebral lesions in the patients with relapsing-remitting MS, with a mean of 30.2 lesions per patient. T1-weighted MPRAGE at 7 Tesla is highly sensitive in detecting multiple sclerosis plaques within white and gray brain matter, and the technique depicted structural damage in each lesion.
Uluslararası (İngilizce): +49 69 797 6602
Bizi Pazartesi - Cuma günleri
8.00 - 17.00 saatleri arasında arayabilirsiniz.
The product is still under development and not commercially available yet. Its future availability cannot be ensured.